OncoMatch/Clinical Trials/NCT05977998
A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology
Is NCT05977998 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Paclitaxel and Dexamethasone for gastric adenocarcinoma.
Treatment: Paclitaxel · Dexamethasone · Diphenhydramine · Famotidine — To learn about the effects of paclitaxel and gastrectomy (surgery to remove all or part of the stomach) on improving outcomes in patients with gastric cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Gastric Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: systemic cytotoxic chemotherapy — preoperative
Completion of preoperative systemic cytotoxic chemotherapy
Lab requirements
Blood counts
Leukocytes 3,000/uL; Absolute neutrophil count 1,500/uL; Platelets 6,000/uL
Kidney function
Serum creatinine 1.6 mg/dL
Adequate renal, and bone marrow function: Leukocytes 3,000/uL; Absolute neutrophil count 1,500/uL; Platelets 6,000/uL; Serum creatinine 1.6 mg/dL
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- M D Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05977998 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received systemic cytotoxic chemotherapy.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages